Related Experiment Video

Updated: Apr 5, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.2K

Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch

Tian Zhang1, Andrew J Armstrong2

  • 1Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|August 27, 2015
PubMed

Insights

Combining a γ-secretase inhibitor with docetaxel shows promise for treating prostate cancer. This Notch pathway inhibition strategy may improve outcomes for men with metastatic prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Notch signaling plays a role in prostate cancer progression.
  • Notch pathway activation contributes to docetaxel resistance in prostate cancer.

Purpose of the Study:

  • To evaluate the combined efficacy of a γ-secretase inhibitor (PF-03084014) and docetaxel.
  • To investigate the underlying mechanisms of this combination therapy in preclinical prostate cancer models.

Main Methods:

  • Utilized preclinical models of prostate cancer.
  • Administered PF-03084014 (a γ-secretase inhibitor) and docetaxel.
  • Assessed additive efficacy and elucidated mechanisms of action.

Main Results:

  • The combination of PF-03084014 and docetaxel demonstrated additive efficacy.
  • Mechanistic insights into the combined therapeutic effect were identified.

Conclusions:

  • Notch pathway inhibition, using γ-secretase inhibitors like PF-03084014, combined with docetaxel, warrants further clinical investigation.
  • This therapeutic approach holds potential for improving treatment outcomes in metastatic prostate cancer.

More Related Videos

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

8.0K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68